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Abstract
Background: Streptococcus pneumoniae is a genetically diverse major human pathogen, yet a
common colonizer of the nasopharynx. Here we analyzed the influence of defects affecting in vitro
growth rate, on the ability of S. pneumoniae to colonize and to cause invasive disease in vivo.
Results: Of eleven different clinical isolates one serotype 14 carrier isolate showed a significantly
longer generation time as compared to other isolates, and was severely attenuated in mice. To
directly investigate the impact of growth rate on virulence, a panel of mutants in five non-essential
housekeeping genes was constructed in the virulent TIGR4 background by insertion-deletion
mutagenesis. Three of these mutants (ychF, hemK and yebC) were, to different degrees, growth
defective, and showed a reduced invasiveness in an intranasal murine challenge model that
correlated to their in vitro growth rate, but remained capable of colonizing the upper airways. The
growth defect, as well as virulence defect of the hemK insertion-deletion mutant, was mediated by
polarity effects on the downstream yrdC  gene, encoding a probable chaperone in ribosome
assembly.
Conclusion:  We conclude that large fitness defects are needed to completely prevent
pneumococci from causing invasive disease after intranasal challenge. However, even severe
growth defects still allow pneumococci to persistently colonize the upper airways.
Background
Streptococcus pneumoniae is one of the major pathogens
infecting humans worldwide. It is the most common
cause of community-acquired bacterial pneumonia and
childhood ear infections, but can also give rise to severe
cases of meningitis and sepsis. It is estimated that 1–2 mil-
lion people die from pneumococcal diseases every year
[1].
The main pneumococcal virulence factor is the antiphago-
cytic capsular polysaccharide, depending on which pneu-
mococci can be divided into at least 91 serotypes [2].
Other virulence factors described include cell wall compo-
nents such as peptidoglycan, teichoic acid, lipoteichoic
acid as well as cell surface proteins such as the choline-
binding proteins [3,4] and the recently described pneu-
mococcal pilus [5]. Signature-tagged mutagenesis (STM)
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has revealed a surprisingly large number of additional loci
required for pneumococcal virulence in mice. Even
though mutants in genes identified by STM are able to
grow in vitro, it is not known to what extent these muta-
tions cause fitness defects that might have an effect on vir-
ulence [6-8].
Despite causing severe diseases, pneumococci are also fre-
quent colonizers of healthy individuals. 60–70% of chil-
dren attending day-care centers may harbor these bacteria
in their nasopharynx [9]. It is not fully understood which
bacterial and host factors that contribute to the transition
from carriage to disease. Invasive disease potential has
been shown to differ between serotypes [10,11], but other
genetic factors are also important for disease outcome in
humans [10,12,13]. Previously we have shown in animal
models that not only serotype, but also clonal type (based
on multi locus sequence typing, MLST and pulsed-field
gel electrophoresis, PFGE), affects clinical outcome [12].
Whether or not variation in growth rate among pneumo-
coccal isolates affects virulence has not been investigated.
Here we monitored the in vitro growth rate for a series of
clinical pneumococcal isolates with different ability to
grow in blood after intraperitoneal challenge of mice [12].
These isolates belong to different serotypes and different
clonal types as determined by MLST. To further evaluate
the impact of in vitro fitness on virulence, we generated
mutants defective in non-essential genes belonging to the
pneumococcal core genome and known to be universally
present in both pathogenic and non-pathogenic bacteria
[14] and therefore unlikely to represent bona fide viru-
lence genes. We find that bacterial fitness defects, as mon-
itored by bacterial growth rates in vitro, proportionally
decreases pneumococcal virulence in animal models,
without abolishing the ability to colonize the upper air-
ways.
Results
In vitro growth rates of pneumococcal isolates and the 
relationship to colonization and virulence in mice
Previously, we studied a collection of clinical pneumococ-
cal isolates of serotypes 1, 4, 6B, 7F, 14 and 19F belonging
to different clonal types [12]. After intranasal challenge
only TIGR4 and isolates of type 6B caused invasive dis-
ease. However, after intraperitoneal challenge both the
median survival time and end-point survival rate differed
between the isolates. TIGR4 and the two isolates of types
6B, 7F and 19F respectively were highly virulent after
intraperitoneal infection, while isolates 1-B, 14-A, 1-A and
14-B were less virulent in decreasing order (Table 1) [12].
More than 90% of the mice survived >216 hours when
inoculated with 14-B as compared to 50% with a chal-
lenge of 14-A.
To investigate whether the differences observed in survival
in vivo could be correlated to differences in fitness, growth
rate estimations and growth curves were made using a
Bioscreen equipment (Figure 1A and 1B). All except one
isolate showed generation times, in semisynthetic c+y
medium, between 33 and 37 minutes. These differences in
growth rates did not fully correspond to the abilities of the
Table 1: Bacterial strains used in this study
Pneumococcal strains Description Source or reference
Clinical isolates
1-A (BHN31) Serotype 1 invasive isolate of ST306 [12]
1-B (BHN32) Serotype 1 invasive isolate of ST228 [12]
6B-A (BHN49) Serotype 6B invasive isolate of ST138 [12]
6B-B (BHN50) Serotype 6B carrier isolate of ST176 [12]
7F-A (BHN55) Serotype 7F invasive isolate of ST191 [12]
7F-B (BHN56) Serotype 7F carrier isolate of ST191 [12]
14-A (BHN78) Serotype 14 invasive isolate of ST124 [12]
14-B (BHN83) Serotype 14 carrier isolate of ST555 [12]
19F-A (BHN100) Serotype 19F carrier isolate of ST162 [12]
19F-B (BHN97) Serotype 19F carrier isolate of ST425 [12]
Laboratory strains
TIGR4 (BHN126) Wild-type strain of serotype 4 (EmS SmS)[ 1 6 ]
TIGR4S (BHN160) TIGR4 spontaneous streptomycin resistant mutant (SmR)T h i s  s t u d y
TIGR4∆ychF (BHN168) ychF (SP0004)::erm (EmR)T h i s  s t u d y
TIGR4∆rluD (BHN169) rluD (SP0929)::erm (EmR)T h i s  s t u d y
TIGR4∆smf (BHN170) smf (SP1266)::erm (EmR)T h i s  s t u d y
TIGR4∆hemK (BHN171) hemK (SP1021)::erm (EmR)T h i s  s t u d y
TIGR4∆yebC (BHN172) yebC (SP1922)::erm (EmR)T h i s  s t u d y
TIGR4ShemK- (BHN173) Point mutations in hemK (SP1021) (SmR)T h i s  s t u d y
TIGR4SyrdC- (BHN174) Point mutations in yrdC (SP1022) (SmR)T h i s  s t u d y
TIGR4SSP1023- (BHN175) Point mutations in SP1023 (SmR)T h i s  s t u d yBMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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same isolates to grow in blood in vivo and to cause sys-
temic disease [12]. Thus, isolate 1-B was more virulent
than 1-A despite that the former isolate showed a slower
in vitro growth rate. Nevertheless, it is interesting to note
that the two 6B isolates showing the highest growth rates
in vitro were the most virulent ones after intraperitoneal
infection in mice. Only the Type14-B carrier isolate exhib-
ited a significantly longer generation time (43 minutes)
compared to all other isolates, which was in line with its
low virulence potential in mice.
Comparative genomic hybridizations were next carried
out on the isolates14-A and 14-B to identify gene content
differences that could explain the fitness defect of the lat-
ter isolate. Microarrays were used, representing the full
genomes of strains R6 [15] and TIGR4 [16]. The invasive
serotype 14 isolate of ST124 (14-A) and the carrier isolate
A) Generation times in c+y of clinical isolates of serotypes 1 (1-A and 1-B), 4 (TIGR4), 6B (6B-A and 6B-B), 7F (7F-A and 7F- B), 14 (14-A and 14-B) and 19F (19F-A and 19F-B) Figure 1
A) Generation times in c+y of clinical isolates of serotypes 1 (1-A and 1-B), 4 (TIGR4), 6B (6B-A and 6B-B), 7F 
(7F-A and 7F-B), 14 (14-A and 14-B) and 19F (19F-A and 19F-B).B) Growth curves of the two type 14 clinical isolates 
in c+y medium and TH medium.
Table 2: Microarray analysis of the clinical isolates 14-A and 14-B with respect to genes identified in STM [6-8]. Gene annotations are 
given according to TIGR4 [16].
Gene Description Ref 14-A ST124 14-B ST555
SP 0071 immunoglobulin A1 protease [6, 8] - +
SP 0143 Hypothetical protein [8] - +
SP 0265 bgla; 6 phospho beta glucosidase [6] - +
SP 0396 mtlf; Mannitol specific enzyme IIA component [6] - +
SP 0474 pts eii; Phosphotransferase system sugar specific EII component [6] - +
SP 1321 v type sodium ATP synthase subunit K [6] - +
SP 1328 sodium:solute symporter family protein [6] - +
SP 0268 alkaline amylopullulanase putative [6] +TIGR4 +R6
SP 0629 conserved hypothetical protein [7] +TIGR4 +R6
SP 0933 pyrroline 5 carboxylate reductase [7] +TIGR4 +R6
SP 1018 tdk; Thymidine kinase [6] +TIGR4 +R6
SP 1029 RNA methyltransferase TrmA family [6] +TIGR4 +R6
SP 1343 ptrb; Protease II (oligopeptidase B) [6] + -
SP 1344 Conserved hypothetical protein [6] + -
SP 1433 Hypothetical protein [6] + -
SP 1434 ABC transporter ATP binding/permease protein [6] + -
SP 2095 Conserved hypothetical protein [6] + -
SP 2164 pts eii; Phosphotransferase system sugar specific EII component [6] + -
Note: Genes that are present are designated +, genes that are absent are designated -. In cases where sequence differences were found between 
the test isolates, subscripts indicate which reference strain the test strain hybridized to.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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of ST555 (14-B) differed from one another at approxi-
mately 196 genes including some variable regions. R6-
specific cluster 4 [17], C11* [17], C13* [17] and most of
TIGR4-specific cluster 7 [17], also known as PPI-1, were
present in 14-A but absent in 14-B. TIGR4-specific cluster
1 and 9 as well as C4*, C5* and part of R6-specific cluster
1 [17] were absent in 14-A, but present in 14-B. In addi-
tion, the two isolates differed from each other at 18 loci
found to affect virulence by signature-tagged mutagenesis
screen (Table 2). Six of these loci were absent in 14-B,
seven were absent in 14-A and five had differences in
sequence between the two isolates. One of the genes that
varied in sequence was SP1018, which is included in the
same operon as hemK (see below). Also, SP1019 of the
hemK operon was missing in the slow-growing 14-B iso-
late, where SP1018 was directly followed by SP1020.
SP1019 has previously been reported to be missing from
some sequenced clinical isolates (see NCBI url in Availa-
bility and requirements section) [18].
Even though we found large differences in the content of
virulence and putative metabolic genes between the two
type 14 isolates, we could not pinpoint one specific gene
responsible for the observed defect in growth and viru-
lence. Therefore we next studied isogenic mutants in con-
served housekeeping genes in the pneumococcal genome.
In vivo studies of isogenic mutants with different 
generation times
To investigate the association between in vitro growth rate
and in vivo ability to colonize and cause systemic disease
insertion-deletion mutants were created in five genes in
TIGR4, one of the most virulent strains in C57BL/6 mice
in our collection. Microarray analysis of 40 pneumococcal
isolates belonging to different serotypes and clones
revealed that all carried the five genes, indicating that they
belong to the pneumococcal core genome (data not
shown). These highly conserved genes are present in all
pathogenic as well as non-pathogenic bacterial species
investigated so far [14], hence it is unlikely that they rep-
resent bona fide virulence genes. They were chosen since
they appear to be house-keeping genes and gene inactiva-
tion would likely lead to fitness defects. They all have
homologues in E. coli, hence we used their E. coli designa-
tions and named the mutants TIGR4∆ychF  (SP0004),
TIGR4∆rluD  (SP0929), TIGR4∆smf  (SP1266),
TIGR4∆hemK  (SP1021) and TIGR4∆yebC  (SP1922).
When in vitro growth rates were measured in c+y semisyn-
thetic medium, the rluD and smf mutants showed almost
wild-type fitness with generation times of 39 and 36 min-
utes respectively, as compared to 37 minutes for the wild-
type TIGR4 strain (p = 0.0596 and p = 0.4452) (Figure 2A
and 2B). However, the insertion-deletion mutants of ychF,
hemK and yebC all had reduced growth rates, 42, 65 and
48 minutes respectively (p = 0.0003, p < 0.0001 and p <
0.0001). The growth defect was especially pronounced for
the hemK mutant, showing smaller colonies on blood agar
plates. The growth differences for the mutant collection
were also recorded in TH medium (Figure 2C). Also in this
medium the hemK mutant showed the most pronounced
growth rate defect and reached a lower density at station-
ary phase.
To mimic the natural route of infection, C57/Bl6 mice
were challenged intranasally with the five insertion-dele-
tion mutants respectively. All mutants gave rise to the
same type of disease, but with different frequencies. For
those mice where bacteria could be cultured from blood,
health status rapidly and irreversibly deteriorated. At the
time of sacrifice all mice with invasive pneumococcal
infection had similar amounts of bacteria in the blood
and lungs (5 × 107 CFU/ml and 1 × 105 CFU/mg respec-
tively), irrespective of challenge strain. Thus, once bacter-
emia occurred, even the severely growth defective hemK
mutant was not cleared from the blood stream. Three of
the five mutants, TIGR4∆ychF, TIGR4∆hemK  and
TIGR4∆yebC, gave a higher end-point survival than the
wild-type TIGR4 strain with 55% (χ2 = 10.25; p = 0.0014),
77% (χ2 = 18.41; p < 0.0001) and 56% (χ2 = 7.369; p =
0.0066) survival respectively by 192 hours, compared to
31% for TIGR4 (Figure 2D). In contrast, TIGR4∆rluD, and
TIGR4∆smf, were not attenuated, with survival rates of
38% (χ2 = 0.3529; p = 0.5525) and 32% (χ2 = 0.0002264;
p = 0.9880) respectively. There was a good relationship
between end-point survival and in vitro growth rate (Fig-
ure 2E). The growth-defective mutants were capable of
colonizing the mice to a similar extent 8 days post infec-
tion as TIGR4 (Figure 2F).
Out of the five mutants, the growth defect was most pro-
nounced for the hemK mutant. Since insertion-deletion
mutagenesis is likely to give polar effects on downstream
genes in the same operon, in-frame mutants were con-
structed in hemK  and in the two genes directly down-
stream of hemK  (SP1022 and SP1023) in order to
pinpoint the responsible gene for the growth defect (Fig-
ure 3). Nucleotides were altered in the 5'-end of the open
reading frames, introducing stop codons. The slow-grow-
ing insertion-deletion mutant of hemK gave smaller colo-
nies than TIGR4 on blood agar plates. Of the in-frame
mutants only the mutant in SP1022 (TIGR4SyrdC-) gave
the same phenotype with small colonies, while the in-
frame mutants of hemK  (TIGR4ShemK-) and SP1023
(TIGR4SSP1023-) both showed wild-type colony size. The
reduced colony size for TIGR4SSP1022- corresponded to a
reduced number of bacteria/colony (6 × 105 as compared
to 2 × 106 for TIGR4S) after 20 hours of incubation on
blood agar plates. Growth rate estimations with Bioscreen
verified that only TIGR4SyrdC- gave a longer generation
time in c+y medium than TIGR4S, 65 minutes as com-BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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pared to 37 minutes (p = 0.0005) (Figures 4A and 4B).
The generation times for TIGR4ShemK-  and
TIGR4SSP1023- were 39 minutes (p = 0.0591) and 38
minutes (p= 0.6780) respectively. The same relative differ-
ences in in vitro growth rate for the different in frame
mutants was also found after growth in TH-medium, with
TIGR4ShemK-  and TIGR4SSP1023-exhibiting similar
growth rate as TIGR4S and TIGR4SyrdC-  exhibiting a
severe growth defect (Figure 4C).
Next, mice were challenged intranasally with TIGR4S,
TIGR4ShemK- or TIGR4SyrdC- (Figure 4D). The survival
rates with TIGR4ShemK-  and TIGR4S were 40% (χ2  =
0.06550; p = 0.7980), with median survival time of 59 h
and 68 h respectively. All mice survived after challenge
with TIGR4SyrdC- (χ2 = 18.03; p < 0.0001). However, 12
out of 14 mice infected with this mutant remained colo-
nized, as determined by CFU count from nasopharyneal-
tracheal lavage at day 8 post-infection (Figure 4E), albeit
at a lower level than those challenged with TIGR4S
(median of 2 × 103 CFU/ml lavage versus 6.8 × 104 CFU/
ml lavage (p = 0.0151)).
Discussion
The pneumococcal genome consists of a core genome rep-
resenting about 70% of the total gene content. The
remaining 30% represents variable genes that may be
present or absent in different isolates (unpublished data).
Several of these variable genes are predicted to have met-
abolic functions, and therefore do not represent true viru-
lence genes, even though in vivo screens using signature-
tagged mutagenesis have identified a number of them as
necessary to cause invasive disease in murine models [6-
8]. Since in vitro fitness might be one explanation for dif-
ferences found in vivo we aimed to determine whether in
vitro fitness, as determined by in vitro growth rates, corre-
lates to virulence in vivo. We used two clinical isolates each
of serotypes 1, 6B, 7F, 14 and 19F with known virulence
in an intraperitoneal mouse model [12] and compared
growth rates with a Bioscreen apparatus. The two isolates
Experiments with insertion-deletion mutants in the TIGR4 background Figure 2
Experiments with insertion-deletion mutants in the TIGR4 background.A) Generation times in c+y medium. B) 
Growth curves in c+y medium. C) Growth curves in TH medium. D) Survival of mice after intranasal infection. E) Generation 
time of mutants versus survival of infected mice. F) Colonization of mice 8 days after intranasal infection.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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of each serotype were chosen to be in most cases one car-
riage isolate and one invasive isolate that were genetically
unrelated based on MLST profiles (Table 1). Differences in
virulence had previously been detected between the two
type 1 isolates, and an even more pronounced difference
was found between the two type 14 isolates [12]. Major
differences in in vitro growth rates between strains of the
same serotype were detected only for type 14 isolates, sug-
gesting in vitro growth to be an important parameter for
the outcome in vivo. The two type 14 isolates were geneti-
cally unrelated by MLST (of ST124 and ST555 respec-
tively) and microarray analysis, differing from each other
at 18 loci found to effect virulence by STM screens (Table
2). Seven of these loci were absent in the more virulent 14-
A isolate, while six were absent in 14-B. In five of the loci
there were differences in sequence between the two iso-
lates, with 14-A carrying genes equal to TIGR4, and 14-B
having the R6 equivalents. Of the genes missing in slow-
growing 14-B, at least two are predicted to be involved in
transport functions (SP1434 and SP2164), but it is not
known if defects in these genes affect growth.
For the two isolates of type 1, the differences in virulence
could not be explained by differences in growth rates. Sev-
eral features, besides growth fitness in a rich complex
medium such as c+y, may influence the disease potential
of a pneumococcal strain including the capsular type
being expressed. This is also reflected by the fact that the
differences seen in in vitro growth rate between the clinical
isolates of different serotypes did not fully correspond to
differences in mice virulence as monitored after intraperi-
toneal challenge. Ability to retrieve carbohydrates from
complex glycoconjugates is likely important for pneumo-
coccal ability to grow in different host environments [19].
Virulence-associated differences among clinical isolates in
carbohydrate retrieval may only be revealed during in vitro
growth using carbon sources mimicking the host environ-
ment, and was not further investigated in this paper.
Instead we attempted to correlate the relationship
between in vitro growth rate and in vivo virulence in mice
creating a panel of mutants in the TIGR4 background defi-
cient in highly conserved non-essential house keeping
genes that were unlikely to affect carbohydrate metabo-
lism of Streptococcus pneumoniae. TIGR4 was used since it
is fully sequenced and since it is the most virulent strain
in our collection after intranasal challenge.
The five candidate genes in the pneumococcal core
genome were chosen based on a previous publication by
Garbom et al. [14]. Garbom et al. showed that these genes
are needed for full virulence of Yersinia in vivo, but they
have only been considered as housekeeping genes in
pneumococci. Their functions have been predicted either
in E. coli or in other species, except for yebC. The E. coli
YchF protein belongs to a group of 11 universally con-
served GTPases [20]. Studies in Haemophilus influenzae
have shown that YchF contains binding sites for both GTP
and double-stranded nucleic acid, indicating that YchF
may be part of a nucleoprotein complex and function as a
GTP-dependant translation factor [21]. rluD  encodes a
The hemK operon and the mutants created in it Figure 3
The hemK operon and the mutants created in it. TIGR4∆hemK was made by insertion-deletion mutagenesis with an 
erythromycin cassette, while the other mutants contain in-frame stop codons (underlined) in the very beginning of the target 
genes. Alterations are shown in bold and the subscripts indicate the nucleotide number of the first alteration in each gene.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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pseudouridine synthase in E. coli which is responsible for
the production of 23S rRNA pseudouridines 1911, 1915
and 1917 [22]. This protein is non-essential in E. coli, but
affects growth [22]. SP0927, which is transcribed
upstream of the pneumococcal homolog to rluD has been
identified as essential for lung infection in mice in a signa-
ture mutagenesis screen (STM) [6]. smf has a homologue
in  H. pylori,  B. subtilis, and Streptococcus pneumoniae,
named dprA (SP1266), and is involved in natural compe-
tence [23-25]. It has only been linked to virulence in Yers-
inia and N. meningitidis [14,26]. The pneumococcal DprA
protein is proposed to play a role in the late stage of trans-
formation, by binding to incoming single stranded DNA
and bringing it to the RecA recombinase. Finally, hemK in
E. coli encodes an N(5)-glutamine methyltransferase that
modifies peptide release factors [27].
Insertion-deletion mutants (potentially creating polar
effects on transcriptionally downstream genes) were con-
structed for all five genes, ychF, rluD, smf, hemK and yebC
in the TIGR4 background. Defects in in vitro growth were
observed for mutants in ychF, hemK and yebC respectively,
where the HemK-deficient mutant was most severely
attenuated with an 80% longer generation time as com-
pared to the wild-type TIGR4. In an intranasal mouse
model of infection, mutations that did not affect in vitro
fitness, i.e. rluD  and  smf, did not influence virulence,
while all mutants with growth defects (ychF, hemK and
yebC) were also attenuated in virulence. The reduction of
virulence correlated to the extent of growth defect
observed. Hence, the hemK mutant was most attenuated,
but still capable of causing severe invasive disease in 27%
of the animals. Long-term colonization of the upper air-
ways was not affected by any of the mutants. Thus, fitness
defects reducing growth rate in vitro did not affect non-
symptomatic carriage, but affected the likelihood of tran-
sition from carriage to invasive disease. However, once
invasive disease occurred there was no apparent effect of a
fitness defect on the progression of invasive disease.
Experiments with in-frame mutants in the TIGR4S background Figure 4
Experiments with in-frame mutants in the TIGR4S background.A) Generation times of strains grown in c+y medium. 
B) Growth curves in c+y medium. C) Growth curves in TH medium. D) Survival of mice after intranasal infection. E) Coloni-
zation of mice 8 days after intranasal infection.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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For the mutants in ychF (SP0004) and yebC (SP1922), we
did not investigate possible effects on neighboring genes.
The pneumococcal homologue to ychF was reported as
potentially essential by Thanassi et al., but Song et al.
showed that this effect was due to polarity [28,29].
Instead Song et al. identified SPR0003, the R6 equivalent
of SP0003, which is probably transcribed together with
ychF, as essential. Therefore, it is possible that the pheno-
type of our ychF insertion-deletion mutant is due to effects
on SP0003 or polar effects on another essential gene
SP0005 [29] encoding a putative peptidyl-tRNA hydro-
lase. Also in the case of yebC (SP1922), interesting genes
can be found in close proximity. About 1 kb downstream
of yebC is ply, encoding the well-known pneumococcal vir-
ulence factor pneumolysin [30]. These genes are however
not believed to be co-transcribed, since the ply gene is
transcribed from its own promoter [31].
In S. pneumoniae, hemK is the fourth gene out of eleven in
an operon that has previously been reported to be associ-
ated with virulence [32,33]. Two groups have reported the
effects of mutations in hemK or the hemK operon in S.
pneumoniae. While Marra et al. observed a significant effect
on virulence, Orihuela et al. did not observe any attenua-
tion [32,33]. Hava and Camilli identified SP1023 (two
genes downstream of hemK) as essential for lung infection
in mice using STM, but did not study the mutant further
[6]. To investigate which gene(s) in this operon was attrib-
uted to the observed defect in growth and virulence, we
constructed in-frame mutants for hemK and the two genes
downstream of hemK, SP1022 and SP1023. The HemK-
deficient insertion-deletion mutant showed smaller colo-
nies on blood agar plates, hence we studied the in-frame
mutants for this phenotype and found it only in the
SP1022 mutant. This mutant also had a considerably
longer generation time in c+y as well as in TH medium
compared to the parental strain, which was not the case
for the other in-frame mutants. Also, the SP1022 mutant
was completely non-virulent in vivo, while the non-polar
hemK in frame mutant gave wild-type virulence. In this set
of experiments all derivatives used carried a mutation in
rpsL giving streptomycin resistance. The lower virulence
observed for TIGR4S as compared to TIGR4 is likely due
to the fitness cost of this rpsL  mutation as previously
shown for Salmonella typhimurium [34]. The complete
attenuation of the in-frame mutation in SP1022 likely
reflects the added fitness defect contributed by the rpsL
mutation. SP1022 is a homologue to yrdC in E. coli, which
was recently reported to be responsible for ribosome mat-
uration [35] and mutations in this gene resulted in severe
defects in growth. Non-ribosomal factors in ribosome
subunit assembly such as YrdC are emerging targets for
new antibacterial drugs [36]. We cannot rule out that also
SP1023 (as well as other genes downstream in the
operon) may be involved in virulence, without affecting in
vitro fitness. SP1023 was picked up in an STM screen by
Hava and Camilli [6]. The method used by Hava and
Camilli to construct the mutant library may have lead to
effects on the expression from neighboring genes within
the operons of the targeted genes. Hence, it is possible that
the phenotype reported for SP01023 is due to effects on
yrdC (SP1022) expression.
Conclusion
Here we found support both among our clinical isolates
studied as well as among the constructed mutants that in
vitro  growth affects invasiveness in vivo. However, all
TIGR4 mutants with reduced growth rate remained capa-
ble of causing severe invasive disease in a fraction of mice,
and were still able to colonize the upper airways to the
same level as the wild-type strain. Also, the slowly grow-
ing ST555 isolate of serotype 14 (14-B) was isolated from
the nasopharynx of a human being. Our results therefore
suggest that pneumococci with metabolic or other fitness
defects may prevail in the carrier population, and poten-
tially also cause invasive disease. Such strains could possi-
bly act as reservoir for the build up of better-fit strains that
also are more capable of generating invasive disease. It is
surprising that so many pneumococcal loci have been
shown, by signature-tagged mutagenesis, to be required
for virulence in mice [6-8]. Revisiting this collection of
mutants, asking which ones also exhibit in vitro fitness
defects, may significantly reduce the number of pneumo-
coccal loci that are directly involved in overcoming host
defenses during invasive disease. Furthermore, it may be
fruitful to identify conserved surface-exposed proteins
that provide a growth defect when inactivated and use
these proteins as drug targets or as recently reported as
vaccine targets [37].
Methods
Bacterial strains used
The bacterial strains used in this study are listed in Table
1. Bacteria were grown on blood agar plates over night,
were resuspended in glucose medium supplemented with
10% horse serum and inoculated 1:10 in semisynthetic
c+y medium [38], and grown until appropriate OD620.
In vitro fitness as determined by monitoring growth
To determine fitness of clinical isolates and mutants, bac-
terial growth in semisynthetic c+y medium [38] was mon-
itored in Bioscreen (Labsystems, Finland). Measurements
were made at OD600 every fifth minute for sixteen hours
and the experiment was repeated three times. Growth
curves were made and generation times were calculated
from the slope of the growth curves at mid-log phase.
Growth curves were also made based on growth in TH
medium.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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Microarray analysis
Comparative genomic hybridizations were carried out on
two type 14 clinical isolates using a reference design as
previously described [39]. Four replicate experiments,
including dye-swap, were performed. Oligonucleotides
were based on predicted open reading frames of the two
sequenced strains R6 [15] and TIGR4 [16]. The data were
analyzed using Genepix pro 6.0 and the R Project for Sta-
tistical Computing (see Availability and requirements sec-
tion for url) as previously described [39]. For statistical
analysis we used a Bayesian linear model [40] and the
Holm multiple testing correction to adjust individual p-
values. This method was used to compare the isolates to
the reference strains. Genes were considered absent if they
had a p-value less then 0.01 within M-value less than -1
and present if they had an M-value of more than -0.8.
Genes were considered to have sequence differences when
one isolate bound to the oligonucleotide corresponding
to R6 and the other to the oligonucleotide corresponding
to TIGR4.
Housekeeping genes selected for further analysis
To study the effect of growth on virulence, five universally
conserved housekeeping genes shown to affect virulence
in Yersinia [14] were selected. All five genes have homo-
logues in E. coli, designated ychF, rluD, smf, hemK  and
yebC. The respective pneumococcal equivalents in the
sequenced TIGR4 and R6 strains are SP0004/SPR0004,
SP0929/SPR0830, SP1266/SPR1144 (dprA), SP1021/
SPR0925 and SP1922/SPR1738 respectively [15,16].
Construction of mutants using insertion-deletion 
mutagenesis
Flanking regions of target genes were amplified from
TIGR4 using specific primers (Appendix) giving either
ApaI or BamHI restriction sites. The erythromycin cassette
from pVA838 [41] was amplified with ApaI and BamHI
termini (Appendix). All fragments were digested and liga-
tions were performed with upstream, downstream and
erythromycin fragments. TIGR4 was transformed with the
ligation products, with selection for EmR. Transforma-
tions were made by adding DNA and CSP-2 [42] to the
recipient pneumococcal strain at OD620 = 0.1, followed by
incubation on ice, at 31°C and finally at 37°C. Trans-
formants were verified by PCR with control primers
(Appendix).
Construction of stop codon mutants (Janus)
Stop codon mutants were constructed for hemK and the
two genes downstream of hemK (SP1022 and SP1023).
These were produced using the Janus cassette [43] with
both positive (kanamycin) and negative (streptomycin)
selection. The wild-type strain was a streptomycin-resist-
ant TIGR4 mutant, TIGR4S, spontaneously obtained
through selection on streptomycin-containing agar plates
and containing a substitution (K56 → R56) in the rpsL
gene, previously reported to cause streptomycin resistance
[44]. A similar construct as for the insertion-deletion
mutants was made, but with the Janus cassette instead of
the erythromycin cassette, using primers DAM406 and
DAM351 [43]. This ligation mix was first transformed into
TIGR4 with selection on kanamycin-containing plates.
PCR was run over the full construct and this fragment in
turn was transformed into TIGR4S. Positive clones of
TIGR4S were then transformed with PCR products con-
taining stop codons. These were introduced about ten
amino acids downstream of the initial ATG.
In vivo studies
5–8 weeks old C57BL/6 mice were inoculated intranasally
with 5 × 106 CFU. Mice were monitored for 8 days to
assess the health status by clinical scoring and blood sam-
ples taken daily. The mice health status was monitored
according to the following scores: 0 = healthy, 1 = pilo-
erection, 2 = reduced motility, 3 = more pronounced
reduced motility, 4 = 1, 2, 3 more pronounced and 5 =
moribund. Mice were sacrificed when they reached score
≥ 3. Surviving mice were killed on day 8 and a nasopha-
ryngealtracheal flush was performed to monitor coloniza-
tion. All experiments were repeated at least three times.
The studies were approved by The Ethical Committee for
Animal Experiments in Stockholm. All animals were kept
with a 12-hours light/dark cycle and had access to stand-
ard food and tap water ad libitum.
Statistical analysis
For survival studies, differences were analysed by the Kap-
lan-Meier analysis log-rank test. The generation times
were analysed using the student t-test (two-tailed).P  <
0.05 was considered significant.BMC Microbiology 2008, 8:65 http://www.biomedcentral.com/1471-2180/8/65
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